金河生物(002688) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 358,633,107.37, down 13.57% year-on-year[8] - Net profit attributable to shareholders was CNY 6,931,601.38, a significant decline of 81.86% compared to the same period last year[8] - Basic earnings per share were CNY 0.01, down 83.33% compared to the same period last year[8] - The weighted average return on net assets was 0.43%, a decrease of 1.89 percentage points year-on-year[8] - Net profit attributable to shareholders decreased by CNY 41,321,238.51, a decline of 28.84%, mainly due to reduced sales of a key product and increased exchange losses[21] - The net profit for the third quarter was CNY 11,107,893.29, compared to CNY 37,524,806.44 in the same period last year, reflecting a significant decline[56] - The total profit for the quarter was CNY 8,363,126.53, down from CNY 47,034,283.86 in the previous year[56] - The net profit attributable to the parent company was CNY 101.94 million, down 28.8% from CNY 143.26 million year-on-year[65] - The total operating revenue for the third quarter was CNY 131,621,328.74, a decrease from CNY 233,848,963.15 in the previous period[59] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 37,009,264.25, a decrease of 60.87% year-on-year[8] - Cash flow from operating activities decreased by CNY 80,029,333.53, a drop of 34.93%, mainly due to increased payments for raw materials and services[23] - Cash and cash equivalents decreased by CNY 118,819,515.64, a reduction of 32.83%, primarily due to cash dividends paid to shareholders[16] - Cash and cash equivalents decreased to approximately CNY 243.09 million from CNY 361.91 million at the end of 2019, representing a decline of about 32.8%[45] - The net cash flow from operating activities for Q3 2020 was ¥149,079,893.69, a decrease of 34.9% compared to ¥229,109,227.22 in Q3 2019[72] - Cash inflow from financing activities was ¥1,152,030,316.69, with cash outflow totaling ¥1,181,293,483.59, leading to a net cash flow of -¥29,263,166.90[73] - The company reported a cash balance of ¥223,686,878.96 at the end of Q3 2020, down from ¥235,363,136.12 at the end of Q3 2019[73] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,279,600,314.42, a decrease of 1.93% compared to the end of the previous year[8] - Total assets amounted to CNY 3,344,278,815.41, with current assets at CNY 1,240,717,688.82 and non-current assets at CNY 2,103,561,126.59[79] - Total liabilities reached CNY 1,537,400,385.63, with current liabilities at CNY 1,145,351,088.56 and non-current liabilities at CNY 392,049,297.07[81] - The total amount of receivables, including accounts receivable and other receivables, is CNY 193,721,748.58[84] - The company holds inventory valued at CNY 429,610,788.66, indicating a strong asset base for operations[79] Changes in Financial Position - Cash and cash equivalents increased by CNY 74,629,273.44, a growth of 97.58%, primarily due to increased bank borrowings to support operations[26] - The company received CNY 158,365,000.00 from other financing activities, an increase of 1,015.16%, mainly from the unfreezing of large deposits[26] - Accounts receivable financing increased by CNY 25,691,786.82, an increase of 35.28%, mainly due to bank acceptance bills used for settlement[16] - Accounts payable decreased by CNY 69,735,692.99, a reduction of 45.88%, primarily due to decreased procurement and payment for raw materials and coal[17] - Contract liabilities increased by CNY 16,845,667.17, attributed to adjustments made under the new revenue recognition standards[17] Financial Expenses and Income - Financial expenses increased by CNY 27,927,050.24, a rise of 109.62%, mainly due to the appreciation of the RMB and increased interest income from bank deposits[18] - Interest income surged by CNY 8,455,934.74, an increase of 1,009.70%, primarily from the unfreezing of large deposits[19] - The company reported a significant increase in financial expenses, amounting to CNY 22,640,180.60, compared to a negative CNY 13,621,506.42 in the previous period[59] - The company incurred income tax expenses of CNY 12.72 million, significantly lower than CNY 34.43 million in the same quarter last year[67] Shareholder and Corporate Actions - The company plans to issue shares through a non-public offering, which was approved in board and shareholder meetings[27] - The company’s controlling shareholder underwent a restructuring, resulting in a change of the controlling entity to Inner Mongolia Jinhai Holdings Co., Ltd.[29] - The company has not engaged in any securities or derivative investments during the reporting period[34][35] - There were no overdue commitments from the actual controller, shareholders, or related parties during the reporting period[33] Research and Development - Research and development expenses amounted to CNY 4,920,646.62, down from CNY 7,113,804.73 in the same period last year[59] - Research and development expenses for the quarter were CNY 20.38 million, a decrease of 10.2% from CNY 22.83 million in the previous year[67] Comprehensive Income - The company reported a decrease in comprehensive income from CNY 5,647,398.42 to CNY -2,963,642.81[48] - The comprehensive income totalled CNY -5,395,373.33 for the quarter, contrasting with CNY 40,471,164.30 in the previous year[57] - The company experienced a loss in comprehensive income attributable to the parent company of CNY -7,101,369.21, compared to CNY 40,724,257.39 in the previous year[57] - The comprehensive income attributable to the parent company was CNY 93.33 million, down from CNY 145.91 million year-on-year[65]